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S182 Oral Presentations3). Fifteen patients had improvement in, or correction of, their un-
derlying PIDD. Although these results are preliminary, our early ex-
perience suggests that outcomes can be improved in high-risk
patients with PIDD by using a modified nonmyeloablative
conditioning regimen and by selecting marrow as the source of he-
matopoietic cells. We observed stable donor engraftment in most
cases, an acceptable TRM, a low incidence of chronic GVHD, and
correction of underlying disease processes.76
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Many patients lack an HLA-matched donor. We evaluated
whether the use of a fixed dose of CD31 cells with megadoses of
CD341 cells from Haplocompatible related donors (HRDs) would
be associated with good outcomes in children.
From 2002 to 2010, we performed a prospective Phase II trial uti-
lizing the CliniMACs (Miltenyi Biotec, Bisley, UK) system to per-
form CD341 cell selection of PBSC from HRDs in 21 pediatric
patients (median age 6.4 yrs, range 1.4-20.5 yrs). 15 patients had a he-
matologicmalignancy (AML/MDS, n5 9; ALL, n5 4; CML, n5 1;
JMML, n 1), 6 patients had a non-malignant condition (Bone Mar-
row Failure, n 5 3; HLH, n 3). Conditioning was TBI 1200 cGy
(200 cGy bid on Days -9 to -7), Thiotepa (5 mg/kg/dose bid on
Day -6), Fludarabine (40mg/m2/dose onDays -6 to -2), andThymo-
globulin (0.5 mg/kg on Day -5, 1 mg/kg on Days -4 to -2). Patients
received a median of 20  106/kg (range: 11-33  106/kg) CD341
cells with 3  104/kg CD31 cells/kg. Events were: graft failure, re-
lapse, and TRM. Statistics were performed using SPSS 16.0. EFS
was estimated using the Kaplan-Meier method.
Engraftment occurred in all but 2 patients (90%; 95% CI, 70-
99%), both with AML/MDS. Relapse occurred in 3 of 15 patients
(20%; 95% CI, 6-46%) at a median of 3.7 months (range: 1.3-12.4
months) post-HCT. All 5 patients eventually expired, despite 2nd
HRD HCT for 4 patients. One or more planned DLI (3  104
CD31 cells/kg) were administered to 11 patients to enhance immu-
nologic recovery. Grade I-II aGVHD was seen in 9 of 19 evaluable
patients (47%; 95% CI, 27-68%). There was no Grade III-IV
aGVHD. cGVHD was seen in 6 of 17 evaluable patients (35%;
95%CI, 17-59%). Infections (Sepsis &Mucor) resulted in the death
of 2 patients (10%; 95% CI, 1-30%) at 11 & 22 months post-HCT;
both were being treated for cGVHD. For all patients, the est. 2-year
EFS was 61% (95% CI, 49-73%). Patients with non-malignant dis-
eases had an est. 2-year EFS of 100% (95% CI, 56-100%). Patients
with malignancy in remission (n 9) had an est. 2-year EFS of 64%
(95% CI, 47-80%), while those not in remission (n 6) had an est.
2-year EFS of only 22% (95% CI, 3-41%). Median follow-up of
survivors was 34 months (range: 3-103 months).
Megadose CD341 cells with a fixed CD31 cell dose from HRDs
resulted in outcomes similar to those seen with other alternative-
donor stem cell sources. For pediatric patients with non-malignant
diseases or those transplanted in remission, outcomes were excellent.77
LUNG BIOPSY IN CHILDREN POST HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
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Sick Children, Toronto, ON, Canada
Introduction: Pulmonary complications are common post hemato-
poietic stem cell transplantation (HSCT). Lung biopsies are invasive
procedures and their utility in the management of care of these pa-
tients is uncertain. This study aims to determine whether the diagno-
ses provided by lung biopsies change the management of care in
a pediatric HSCT patient population.Methods: We retrospectively reviewed charts from patients who
had a lung biopsy after a HSCT at The Hospital for Sick Children
in Toronto, Canada. The results of the lung biopsies were correlated
with the clinical management pre- and post-biopsy.
Results: From January 2000 to June 2010, 918 patients received
HSCT (allogeneic 476, autologus 442). A total of 59 biopsies
were performed in 48 patients (ages 6 months -17 years). Of the
48 patients, 32 patients received allo HSCT (20- malignant and
12- non-malignant) and 16 patients received auto HSCT. Biopsies
were open lung biopsies via a thoracotomy (38), thoracoscopic (9),
and percutaneous needle biopsy (12). The median time from
HSCT to biopsy was 3 months (range 7 days – 50 months). The
primary diagnosis from the biopsies was lung damage (vasculop-
athy, type II pneumocyte hyperplasia) attributed to drug or radia-
tion toxicity in 15 patients (25%). This was followed by recurrence
or metastasis of the primary malignant disease in 13 (22%), diffuse
alveolar damage in 10 (17%), interstitial inflammation in 7 (12%),
confirmed infection in 5 (8%), interstitial pneumonitis in 3 (5%),
BO(OP) in 2 (3%), ARDS in 1 (2%), pneumonia without an organ-
ism in 1(2%), pulmonary alveolar protienosis in 1 (2%) and nega-
tive findings in 1 patient (2%). Apart from the patients with
recurrent malignant disease results on biopsy, there were no major
changes in patients’ management of care after the lung biopsy.
Thirty-three patients died after the lung biopsy (68.75%) at a me-
dian of 1 month (range 1 day – 55 months). Cause of death in these
patients was primarily respiratory failure in 16 (48%) followed by
progression of malignant disease in 12 (36%), cardiac arrest in 3
(9%), infection in 1 (3%), GvHD 1 (3%). Death was most common
in patients who had open lung biopsies; 66% of open lung biopsies
were followed by death.
Conclusions: A decision to perform a lung biopsy in children post
HSCT is an indicator for poor prognosis. Apart from confirming
malignant progression or rare infectious microorganisms, results
from lung biopsies did not alter their management significantly.78
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PLANT CONDITIONING FOR MATCHED UNRELATED DONOR ALLOGE-
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Current treatment algorithms for pediatric severe aplastic anemia
(SAA) entail up-frontmatched sibling donor (MSD)HCT, or immu-
nosuppressive therapy for those withoutMSD. To assess whether an
immunoablative tolerance-induction regimen for unrelated (MUD)
HCT could be applied to extend up-front application of HCT in
SAA, we retrospectively reviewed our single-institution HCT
experience from 1999-2009 (minimum 1-year follow-up) for SAA
patients using unmanipulated bone marrow grafts from high-resolu-
tion 10/10 HLA-matched donors. Conditioning (cumulative dose)
was cyclophosphamide 200 mg/kg (CTX) 1 rabbit ATG 10 mg/kg
(rATG) for MSD (n 5 9) versus total lymphoid irradiation (TLI,
800 cGy) 1 CTX/rATG for MUD HCT (n 5 5). Immunoprophy-
laxis was cyclosporine A (CSA) and short-course methotrexate for all
patients. Ten of 14 patients were Caucasian, 7 were female, median
age at time of HCT was 14.7 years (range, 4.6 - 19.3), and median
follow-up 3.0 years (range, 1.1 - 10.3). All patients were chronically
platelet and erythrocyte transfusion-dependent at HCT. Mean
CD341 cell dose (MSD: 6.2 64.2  106/kg; MUD: 3.9 62.4 
106/kg) and mean CD31 cell dose (MSD: 28.3 616.2  106/kg;
MUD: 29.4 615.8  106/kg) were not significantly different be-
tween groups. Themajor outcomemeasures were event-free survival
(EFS), engraftment rate, time to engraftment, and cumulative inci-
dence of GVHD within 1 year (CIN of GVHD) for MSD and
MUD cohorts. The EFS and stable engraftment rates were 100%
for MSD and MUD, and time to engraftment of ANC and platelets
was not significantly different between MSD and MUD (p . 0.25).
CIN of acute GVHD was: MSD, Grade I-II: 11%, Grade III-IV:
